Nucleotides

Adenosine-5′-triphosphate (ATP), cytidine-5′-triphosphate (CTP), guanosine-5′-triphosphate (GTP), and uridine-5′-triphosphate (UTP) are unmodified ribonucleoside triphosphates, serving as essential building blocks of RNA molecules. Each of them consists of an unmodified base, a ribose, and a 5′ triphosphate group. They can be used with modified nucleotides and TriLink’s patented CleanCap® capping technology in in vitro transcription for robust RNA manufacturing.

Adenosine-5′-triphosphate (ATP), cytidine-5′-triphosphate (CTP), guanosine-5′-triphosphate (GTP), and uridine-5′-triphosphate (UTP) are unmodified ribonucleoside triphosphates, serving as essential building blocks of RNA molecules. Each of them consists of an unmodified base, a ribose, and a 5′ triphosphate group. They can be used with modified nucleotides and TriLink’s patented CleanCap® capping technology in in vitro transcription for robust RNA manufacturing.

Ribonucleoside triphosphates (rNTPs) are the building blocks of RNA molecules and are essential to the success of RNA drug development. TriLink’s rNTPs are manufactured under stringent quality standards in an ISO-9001 certified facility, offering exceptional quality, purity, and consistency. They are ideally suited for RNA synthesis in research, diagnostics, therapeutics, and vaccine development. Substituting uridines with modified uridines, such as N1-methylpseudouridine, 5-methoxyuridine, and pseudouridine, can reduce immunogenic response and enhance translational efficiency of mRNAs. These properties can result in safer mRNA and increased protein expression. The rNTP set with N1-methylpseudo-UTP contains separate tubes of 100 mM ATP, CTP, GTP, and N1MePs-UTP in H2O, pH 7.5. The rNTPs can be used with TriLink’s patented CleanCap® capping technology in in vitro transcription for robust RNA manufacturing.

Ribonucleoside triphosphates (rNTPs) are the building blocks of RNA molecules and are essential to the success of RNA drug development. TriLink’s rNTPs are manufactured under stringent quality standards in an ISO-9001 certified facility, offering exceptional quality, purity, and consistency. They are ideally suited for RNA synthesis in research, diagnostics, therapeutics, and vaccine development. Substituting uridines with modified uridines, such as N1-methylpseudouridine, 5-methoxyuridine, and pseudouridine, can reduce immunogenic response and enhance translational efficiency of mRNAs. These properties can result in safer mRNA and increased protein expression. The rNTP set with 5-methoxy-UTP contains separate tubes of 100 mM ATP, CTP, GTP, and 5mo-UTP in H2O, pH 7.5. The rNTPs can be used with TriLink’s patented CleanCap® capping technology in in vitro transcription for robust RNA manufacturing.

Ribonucleoside triphosphates (rNTPs) are the building blocks of RNA molecules and are essential to the success of RNA drug development. TriLink’s rNTPs are manufactured under stringent quality standards in an ISO-9001 certified facility, offering exceptional quality, purity, and consistency. They are ideally suited for RNA synthesis in research, diagnostics, therapeutics, and vaccine development. Substituting uridines with modified uridines, such as N1-methylpseudouridine, 5-methoxyuridine, and pseudouridine, can reduce immunogenic response and enhance translational efficiency of mRNAs. These properties can result in safer mRNA and increased protein expression. The rNTP set with pseudo-UTP contains separate tubes of 100 mM ATP, CTP, GTP, and pseudo-UTP in H2O, pH 7.5. The rNTPs can be used with TriLink’s patented CleanCap® capping technology in in vitro transcription for robust RNA manufacturing.